27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna (NASDAQ:MRNA) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 8% of the investors opened trades with bullish expectations and 91% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $229,472 and 8, calls, for a total amount of $475,300.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $130.0 for Moderna during the past quarter.
Volume & Open Interest Trends
In today's trading context, the average open interest for options of Moderna stands at 526.33, with a total volume reaching 922.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $50.0 to $130.0, throughout the last 30 days.
Moderna Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | TRADE | BULLISH | 07/19/24 | $50.00 | $164.7K | 57 | 27 |
| MRNA | PUT | SWEEP | NEUTRAL | 01/19/24 | $107.00 | $140.2K | 181 | 98 |
| MRNA | CALL | TRADE | NEUTRAL | 01/17/25 | $85.00 | $88.2K | 175 | 33 |
| MRNA | CALL | SWEEP | BEARISH | 06/21/24 | $130.00 | $40.8K | 1.6K | 61 |
| MRNA | CALL | TRADE | BEARISH | 01/26/24 | $100.00 | $39.6K | 234 | 44 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is Moderna Standing Right Now?
- Currently trading with a volume of 1,955,234, the MRNA's price is down by -1.33%, now at $108.72.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 43 days.
What The Experts Say On Moderna
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $142.0.
- In a positive move, an analyst from Oppenheimer has upgraded their rating to Outperform and adjusted the price target to $142.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!